跳至主要内容
临床试验/NCT06178354
NCT06178354招募中不适用

A Pragmatic Phase 2 Study of Focal Ablation (Focal Cryotherapy or High Intensity Frequency Ultrasound) in Men With Clinically Localized Prostate Cancer

University of California, Davis2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年11月9日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
2
主要终点
Pathologic outcome on surveillance prostate biopsy

研究概览

简要总结

This clinical trial evaluates the effectiveness of focal ablation with either focal cryotherapy or high intensity frequency ultrasound for the treatment of men with localized prostate cancer. Focal cryotherapy kills tumor cells by freezing them. High intensity frequency ultrasound uses highly focused ultrasound waves to produce heat and destroy tumor cells.

详细描述

PRIMARY OBJECTIVE:

I. To determine the efficacy of focal therapy for treatment of prostate cancer.

SECONDARY OBJECTIVES:

I. Patient reported urinary, sexual function and quality of life (QOL) at 1 year.

II. To assess safety.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Ability to understand and willingness to sign an informed consent form
  • Clinically localized grade group 1, 2, or 3 prostate cancer and unilateral magnetic resonance imaging (MRI) visible lesion(s). Up to 3 lesions will be allowed for focal treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (Karnofsky ≥ 70%)
  • Patients ≥ 18 years of age at time of consent
  • Life expectancy ≥ 5 years
  • Ability and stated willingness to adhere to the study visit schedule and other protocol procedures/requirements for the duration of the study

排除标准

  • Nodal or distant metastases
  • Prior treatment for prostate cancer
  • Anticipated treatment with any cancer intervention, including radiation, hormonal therapy or surgery ≤ 6 months prior to focal therapy in this study
  • Known contraindications to general anesthesia
  • Uncorrectable coagulopathy
  • Significant active cardiac disease within the previous 6 months including: New York Heart Association (NYHA) class 4 congestive heart failure (CHF), unstable angina, or myocardial infarction
  • Any condition that would prohibit the understanding or rendering of informed consent
  • Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on trial

研究组 & 干预措施

Treatment (cryosurgery, high intensity focused ultrasound)

Experimental

Patients undergo focal cryotherapy or high intensity focused ultrasound on study.

干预措施: Cryosurgery (Procedure)

Treatment (cryosurgery, high intensity focused ultrasound)

Experimental

Patients undergo focal cryotherapy or high intensity focused ultrasound on study.

干预措施: High-Intensity Focused Ultrasound Ablation (Procedure)

Treatment (cryosurgery, high intensity focused ultrasound)

Experimental

Patients undergo focal cryotherapy or high intensity focused ultrasound on study.

干预措施: Survey Administration (Other)

结局指标

主要结局

Pathologic outcome on surveillance prostate biopsy

时间窗: At year 1 and 3

Confidence intervals for the pathologic response rate will be calculated using the Wilson score method. Pathologic response rate will be analyzed by baseline clinical and molecular characteristics using univariable and multivariable logistic regression.

Proportion of participants who go onto whole gland salvage treatment

时间窗: At 3 years

Will be estimated using the Kaplan-Meier method.

Salvage whole gland treatment free survival

时间窗: At 3 years

Will be analyzed by baseline clinical and molecular characteristics using univariable and multivariable Cox proportional hazards models.

次要结局

  • Quality of life(At 1 year)
  • Adverse events(Up to end of treatment visit, approximately 7-14 days after treatment)
  • Sexual function(At 1 year)
  • Urinary function(At 1 year)

研究者

申办方类型
Other
责任方
Sponsor
主要研究者

Marc Dall'Era, MD

Principal Investigator

University of California, Davis

研究点 (2)

Loading locations...

相似试验